Related Experiment Videos
Clinical results with the AB-180 left ventricular assist device
J A Magovern1, M J Sussman, A H Goldstein
1Department of Cardiothoracic Surgery, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA. jmagover@wpahs.org
The Annals of Thoracic Surgery
|March 27, 2001
Summary
The AB-180 ventricular assist device provided reliable support in 17 patients with reversible heart failure. Overall weaning and survival rates were 58% and 29%, respectively, with no major device complications.
Area of Science:
- Cardiology
- Medical Devices
- Clinical Trials
Background:
- Initial clinical experience with the AB-180 ventricular assist device.
- Focus on device reliability and patient outcomes.
Purpose of the Study:
- To evaluate the initial clinical performance of the AB-180 ventricular assist device.
- To assess patient outcomes including weaning and survival rates.
Main Methods:
- Implantation of the AB-180 device in 17 patients between December 1997 and July 2000.
- Patients presented with indications including postcardiotomy shock, decompensated cardiomyopathy, viral myocarditis, and acute myocardial infarction.
- Mean patient age was 52 years, with 14 males.
Main Results:
- Mean duration of support was 8.5 days.
- Eight patients were weaned, and two underwent transplantation.
- Overall weaning rate was 58% (10/17), and overall survival rate was 29% (5/17).
- No major device-related complications or malfunctions were reported.
Conclusions:
- The AB-180 ventricular assist device offers reliable circulatory support.
- The device is effective for patients experiencing reversible forms of heart failure.